{
    "Trade/Device Name(s)": [
        "ADVIA Chemistry Triglycerides_2 Assay (TRIG_2)",
        "ADVIA Chemistry Triglycerides_2 (TRIG_2) Reagent"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics, Inc.",
    "510(k) Number": "K133067",
    "Predicate Device Reference 510(k) Number(s)": [
        "K010871"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "CDT"
    ],
    "Summary Letter Date": "September 26, 2013",
    "Summary Letter Received Date": "September 27, 2013",
    "Submission Date": "September 26, 2013",
    "Regulation Number(s)": [
        "21 CFR 862.1705"
    ],
    "Regulation Name(s)": [
        "Triglyceride test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Triglycerides"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Lithium Heparin tube",
        "Potassium EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ADVIA 1800 Chemistry System"
    ],
    "Method(s)/Technology(ies)": [
        "Enzymatic assay",
        "Fossati three-step enzymatic reaction",
        "Trinder endpoint"
    ],
    "Methodologies": [
        "Quantitative measurement",
        "Endpoint spectrophotometry"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for ADVIA Chemistry Triglycerides_2 reagent for quantitation of triglycerides in serum and plasma using the ADVIA 1800 system",
    "Indications for Use Summary": "Intended for in vitro diagnostic quantitative measurement of triglycerides in human serum and plasma to aid diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, lipid metabolism diseases, or various endocrine disorders",
    "fda_folder": "Clinical Chemistry"
}